Phoenix (Ariz.) Children’s Hospital has secured more than $3.2 million in grant funding to support new research in pediatric neurology, cardiology, lung disease and infectious disease.
The Arizona Biomedical Research Centre awarded $750,000 to support gene-targeting therapies for neurodevelopmental disorders such as autism and epilepsy, according to a Dec. 30 news release from the health system. A separate $2.5 million grant from the National Heart, Lung and Blood Institute is backing research into therapies for pulmonary fibrosis.
Researchers at Phoenix Children’s also led or co-authored recent multicenter studies on pediatric stroke, brain tumors and cardiac complications tied to COVID-19. One study evaluated 205 children with arterial ischemic stroke and found a potential link between varicella zoster virus and stroke risk, even in vaccinated patients.
Another study, involving more than 1,200 patients from 32 North American pediatric hospitals, tracked six-month outcomes of children with multisystem inflammatory syndrome (MIS-C). Researchers concluded most patients had favorable cardiovascular recovery after initial severe illness.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
